Inhibition of osteoblastic metalloproteinases in mice prevents bone loss induced by oestrogen deficiency

Journal of Cellular Biochemistry

Volumn 104, Issue 5, 2008, Pages 1803-1817

  Schiltz, Corinne ^a,b   Marty, Caroline ^a,b   De Vernejoul, Marie Christine ^a,b   Geoffroy, Valerie ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Matrix metalloproteinases; Oestrogen; Osteoporosis; TGF 1; TIMP 1; Transgenic mice

Indexed keywords

ESTRADIOL; ESTROGEN; METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PYRIDINOLINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITOMETRY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; EX VIVO STUDY; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; STEM CELL; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BIOLOGICAL MARKERS; BONE RESORPTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 3; METALLOPROTEASES; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; OVARIECTOMY; RANK LIGAND; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

MUS; MUS MUSCULUS;

EID: 50249095608     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21747     Document Type: Article

References (55)

1. Andersen TL, Del Carmen Ovejero M, Kirkegaard T, Lenhard T, Foged NT, Delaisse JM. 2004. A scrutiny of matrix metalloproteinases in osteoclasts: Evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone 35:1107-1119.
2. Beaudreuil J, Mbalaviele G, Cohen-Solal M, Morieux C, De Vernejoul MC, Orcel P. 1995. Short-term local injections of transforming growth factor-beta 1 decrease ovariec-tomy-stimulated osteoclastic resorption in vivo in rats. J Bone Miner Res 10:971-977.
3. Bouxsein ML, Myers KS, Shultz KL, Donahue LR, Rosen CJ, Beamer WG. 2005. Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res 20:1085-1092.
4. Breckon JJ, Papaioannou S, Kon LW, Tumber A, Hembry RM, Murphy G, Reynolds JJ, Meikle MC. 1999. Stromelysin (MMP-3) synthesis is up-regulated in estrogendeficient mouse osteoblasts in vivo and in vitro. J Bone Miner Res 14:1880-1890.
5. Burrage PS, Mix KS, Brinckerhoff CE. 2006. Matrix metalloproteinases: Role in arthritis. Front Biosci 11: 529-543.
6. Chambers TJ, Fuller K. 1985. Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J Cell Sci 76:155-165.
7. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. 2002. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277:21352=21360.
8. De Becker A, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, De Waele M, Van Riet I. 2007. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 92:440-449.
9. Delaisse JM, Engsig MT, Everts V, del Carmen Ovejero M, Ferreras M, Lund L, Vu TH, Werb Z, Winding B, Lochter A, Karsdal MA, Troen T, Kirkegaard T, Lenhard T, Heegaard AM, Neff L, Baron R, Foged NT. 2000. Proteinases in bone resorption: Obvious and less obvious roles. Clin Chim Acta 291:223-234.
10. Everts V, Delaisse JM, Korper W, Beertsen W. 1998. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res 13:1420-1430.
11. Everts VKW, Hoeben KA, Jansen ID, Bromme D, Cleutjens KB, Heeneman S, Peters C, Reinheckel T, Saftig P, Beertsen W. 2006. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: Differences between calvaria and long bone. J Bone Miner Res 21: 1399-1408.
12. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H, Maskos K. 1998. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 17:5238-5248.
13. Finkelman RD, Bell NH, Strong DD, Demers LM, Baylink DJ. 1992. Ovariectomy selectively reduces the concentration of transforming growth factor beta in rat bone: Implications for estrogen deficiency-associated bone loss. Proc Natl Acad Sci USA 89:12190-12193.
14. Fox SW, Haque SJ, Lovibond AC, Chambers TJ. 2003. The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol 170:3679-3687.
15. Fratzl-Zelman N, Glantschnig H, Rumpler M, Nader A, Ellinger A, Varga F. 2003. The expression of matrix metalloproteinase-13 and osteocalcin in mouse osteoblasts is related to osteoblastic differentiation and is modulated by 1,25-dihydroxyvitamin D3 and thyroid hormones. Cell Biol Int 27:459-468.
16. Gao YQW, Dark K, Toraldo G, Lin AS, Guldberg RE, Flavell RA, Weitzmann MN, Paciflci R. 2004. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA 101: 16618-16623.
17. Geoffroy V, Le Goupil N, Clement-Lacroix P, Terraz C, Frain M, Roux S, Rossert J, de Vernejoul MC. 2004. In vivo inhibition of osteoblastic metalloproteinases leads to increased trabecular bone mass. J Bone Miner Res 19: 811-822.
18. Hikita A, Yana I, Wakeyama H, Nakamura M, Kadono Y, Oshima Y, Nakamura K, Seiki M, Tanaka S. 2006. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 28:36846-36855.
19. Hill PA, Murphy G, Docherty AJ, Hembry RM, Millican TA, Reynolds JJ, Meikle MC. 1994. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci 107:3055-3064.
20. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. 1999. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367-4370.
21. Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL. 1997. Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 272:22053-22058.
22. Holmbeck K, Bianco P, Yamada S, Birkedal-Hansen H. 2004. MT1-MMP: A tethered collagenase. J Cell Physiol 200:11-19.
23. Hou P, Troen T, Ovejero MC, Kirkegaard T, Andersen TL, Byrjalsen I, Ferreras M, Sato T, Shapiro SD, Foged NT, Delaisse JM. 2004. Matrix metalloproteinase-12 (MMP-12) in osteoclasts: New lesson on the involvement of MMPs in bone resorption. Bone 34:37-47.
24. Inada MWY, Byrne MH, Rahman MU, Miyaura C, Lopez-Otin C, Krane SM. 2004. Critical roles for collagenase-3 (Mmpl3) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA 101: 17192-17197.
25. Iwaniec UT, Yuan D, Power RA, Wronski TJ. 2006. Strain-dependent variations in the response of cancellous bone to ovariectomy in mice. J Bone Miner Res 21:1068-1074.
26. Kanis JA. 2002. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936.
27. Karsdal MA, Fjording MS, Foged NT, Delaisse JM, Lochter A. 2001. Transforming growth factor-beta-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J Biol Chem 276:39350-39358.
28. Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, Delaisse JM, Foged NT. 2002. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277:44061-44067.
29. Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaisse JM, Foged NT. 2003. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975-44987.
30. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K. 2007. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487-494.
31. Karst M, Gorny G, Sells Galvin RJ, Oursler MJ. 2004. Roles of stromal cell RANKL, OPG, and M-CSF: Expression in biphasic tgf-b regulation of osteoclast differentiation. J Cell Physiol 200:99-106.
32. Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E. 2005. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36:159-172.
33. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK. 2005. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584-4596.
34. Lindberg MK, Moverare S, Eriksson AL, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, Ohlsson C. 2002. Identification of estrogen-regulated genes of potential importance for the regulation of trabecular bone mineral density. J Bone Miner Res 17:2183-2195.
35. Lindberg MK, Svensson J, Venken K, Chavoshi T, Andersson N, Moverare Skrtic S, Isaksson O, Vanderschueren D, Carlsten H, Ohlsson C. 2006. Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss. Bone 38:85-92.
36. Malemud CJ. 2006. Matrix metalloproteinases: Role in skeletal development and growth plate disorders. Front Biosci 11:1702-1715.
37. Meikle MC, Bord S, Hembry RM, Compston J, Croucher PI, Reynolds JJ. 1992. Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines. J Cell Sci 103:1093-1099.
38. Merciris D, Schiltz C, Legoupil N, Marty-Morieux C, de Vernejoul MC, Geoffroy V. 2007. Over-expression of TIMP-1 in osteoblasts increases the anabolic response to PTH. Bone 40:75-83.
39. Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, Diouri J, Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M, Doty SB, Majeska RJ, Schaffler MB, Martignetti JA. 2007. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet 16:1113-1123.
40. Nakashima A, Tamura M. 2006. Regulation of matrix metalloproteinase-13 and tissue inhibitor of matrix metalloproteinase-1 gene expression by WNT3A and bone morphogenetic protein-2 in osteoblastic differentiation. Front Biosci 11:1667-1678.
41. Otsuka K, Sodek J, Limeback H. 1984. Synthesis of collagenase and collagenase inhibitors by osteoblast-like cells in culture. Eur J Biochem 145:123-129.
42. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. 1987. Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
43. Qu Q, Perala-Heape M, Kapanen A, Dahllund J, Salo J, Vaananen HK, Harkonen P. 1998. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 22:201-209.
44. Raisz LG. 2005. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 115:3318-3325.
45. Riggs BL. 2000. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 106:1203-1204.
46. Riggs BL, Khosla S, Melton LJ III. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302.
47. Selvamurugan N, Kwok S, Alliston T, Reiss M, Partridge NC. 2004. Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2. J. Biol Chem 279:19327-19334.
48. Sternlicht MD, Werb Z. 2001. Matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516.
49. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P, Werb Z. 2004. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 131:5883-5895.
50. Uchida M, Shima M, Shimoaka T, Fujieda A, Obara K, Suzuki H, Nagai Y, Ikeda T, Yamato H, Kawaguchi H. 2000. Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells. J Cell Physiol 185:207-214.
51. VanSaun MN, Matrisian LM. 2006. Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 78:69-79.
52. Varghese S. 2006. Matrix metalloproteinases and their inhibitors in bone: An overview of regulation and functions. Front Biosci 11:2949-2966.
53. Weitzmann MN, Pacifici R. 2006. Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 116:1186-1194.
54. Williams S, Barnes J, Wakisaka A, Ogasa H, Liang CT. 1999. Treatment of osteoporosis with MMP inhibitors. Ann NY Acad Sci 878:191-200.
55. Zhao W, Byrne MH, Wang Y, Krane SM. 2000. Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen. J Clin Invest 106:941-949.